Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation

For the Fukuoka Blood and Marrow Transplantation Group

研究成果: Contribution to journalArticle

抜粋

Outcomes for patients with multiple myeloma (MM) have improved through use of novel treatments, especially lenalidomide combined with autologous stem cell transplantation. However, because of their increased life expectancy, an increased risk of secondary primary malignancies (SPMs) has been observed in MM patients, particularly after lenalidomide maintenance in both transplant-eligible (TE) and transplant-ineligible (TI) patients. To evaluate the incidence and risk factors of developing SPMs, we identified 17 TE-MM and 12 TI-MM patients with SPMs among 211 TE-MM and 280 TI-MM patients, including seven TE-MM and four TI-MM patients with hematological malignancies and ten TE-MM and eight TI-MM patients with non-hematological cancers, respectively. The median follow-up time from diagnosis was > 4 years. Multivariate analysis identified a history of high-dose cyclophosphamide use for peripheral blood stem cell harvest in TE-MM patients and > 65 years of age at diagnosis, or a history of adriamycin, lenalidomide, or thalidomide use in TI-MM patients as independent risk factors for SPMs (P < 0.001). Patients with a history of lenalidomide use had a lower risk of death among both TE-MM (P = 0.0326) and TI-MM (P < 0.001) patients. The survival benefit of receiving lenalidomide outweighed the increased risk of SPMs in both TE-and TI-MM patients.

元の言語英語
ページ(範囲)98-106
ページ数9
ジャーナルInternational journal of hematology
109
発行部数1
DOI
出版物ステータス出版済み - 1 22 2019

All Science Journal Classification (ASJC) codes

  • Hematology

フィンガープリント Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用